Medicure completes enrollment in MEND-PNPO Phase 3 trial of MC-1 for PNPO deficiency

By Public Technologies
  • Medicure completed patient enrollment in the MEND-PNPO Phase 3 trial of MC-1 for PNPO deficiency, reaching its target of 10 patients.
  • Participants are moving through treatment and follow-up, positioning the program toward a potential future NDA submission.
  • Trial design and baseline data were already presented at the European Epilepsy Congress.
  • The same data will be presented later this year at the Child Neurology Society Annual Meeting and the American Epilepsy Society Annual Meeting.
  • MC-1 holds FDA Rare Pediatric Disease, Orphan Drug, Fast Track designations, supporting a faster review pathway and potential Priority Review Voucher eligibility.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medicure Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202609281800ACCESSWRNAPR_____1228105) on September 28, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.